Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Vital Edge

Two GLP-1 desks, one scoreboard. We put Sesame Care and Vital Edge head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 300 · Grade C

Vital Edge

Visit Vital Edge Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 62 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Vital Edge a bad call — it's best for people who want transparent flat-fee glp-1 pricing with oral and brand-name options. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
58
Supply Reliability
92
76
Transparency
94
32
Access Breadth
84
62
Clinical Oversight
80
80
Track Record
92
68
Sesame CareBrief Score 87 · 62Vital Edge

Price, coverage & the tracker

Sesame CareVital Edge
Brief Score87/100 (B+)62/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)From $199/mo (compounded oral)
TirzepatideBrand Zepbound (price varies)From $269/mo (compounded oral)
CoverageNationwide marketplaceCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Vital Edge: New to the tracker on 1 August 2026. The published line reads From $199/mo (compounded oral) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.